ArticleComputational and structural biotechnology journal2025
LC-MS/MS identifies elevated imidazole propionate and gut-derived metabolite alterations in peritoneal dialysis patients.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.Gut microbes · 2026Review
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed a robust LC-MS/MS method for the simultaneous quantification of 16 uremic toxins (UTs) and 14 bile acids (BAs) in plasma and fecal samples within a single method. The method demonstrated high sensitivity, broad metabolite coverage, and excellent accuracy, precision, and throughput. Using this platform, targeted metabolites were quantified in peritoneal dialysis (PD) patients (n = 31) and healthy controls (HC; n = 60). Of the 30 targeted metabolites included in the validation method, 20 were detected in fecal samples and 12 in plasma in this study. Fecal samples exhibited greater BA diversity, whereas UTs were evenly distributed across both matrices. Fecal profiles showed minimal differences between PD and HC, suggesting limited gut-level alteration. In contrast, plasma analysis revealed nine metabolites significantly elevated in PD, including indoxyl sulfate, phenyl sulfate, hippuric acid, and imidazole propionate (ImP), lithocholic acid, cinnamoylglycine, m-hydroxyhippuric acid, phenylacetylglutamine, and phenylacetylglycine. Notably, plasma ImP-an underexplored metabolite-was elevated independently of diabetes or cardiovascular disease, implicating impaired renal clearance as its primary driver. These results highlight the systemic impact of gut-derived metabolites in kidney failure and position targeted UT-BA profiling as a powerful complementary tool for clinical metabolomics in chronic kidney disease and PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.